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Ambroxol is a pharmacological chaperone (PC) for Gaucher disease that increases 
lysosomal activity of misfolded -glucocerebrosidase (GCase) while displaying a safe 
toxicological profile. In this work we have developed different poly(-caprolactone) 
(PCL)-based systems to regulate the sustained release of small polar drugs in 
physiological environments. For this purpose, ambroxol has been selected as test case 
since the encapsulation and release of PCs using polymeric scaffolds have not been 
explored yet. More specifically, ambroxol has been successfully loaded in electrospun 
PCL microfibers, which have been subsequently coated with additional PCL layers 
using dip-coating or spin-coating. The time needed to achieve 80% release of loaded  
ambroxol increases from 15 min for uncoated fibrous scaffolds to 3 days and 1 week 
for dip-coated and spin-coated systems, respectively. Furthermore, we have proved that 







Existing polymer-based drug delivery systems can be divided into two groups based 
on their mode of administration. The first relies on systemic delivery and consists of 
nano-materials such as polymer nanoparticles, liposomes, and dendrimers. These 
delivery vehicles, which are predominantly intended for oral or intravenous 
administration, find their target by passive diffusion or by triggering the release of 
payload from an environment-responsive nano-carrier using a local stimulus (i.e. pH, 
temperature, etc). However, systemic delivery may result in suboptimal drug therapeutic 
concentration, leading to erroneous conclusions regarding agent efficacy. The second 
group of polymer delivery vehicles (and focus of this research) includes controlled 
release drug delivery depot systems for implantation inside or adjacent to the target 
tissue. The majority of these local polymer device systems are biodegradable so as to 
circumvent a second surgery for device removal and to avoid a chronic foreign-body 
immune response. The polymers used in these systems are often hydrophobic in nature, 
and are ideally suited for long-term delivery and internal stabilization of sensitive water-
insoluble hydrophobic drugs. Nevertheless, long-term delivery of polar drugs remains a 
challenge since they are rapidly extracted from the vehicle by the aqueous environment 
of the target, making difficult the achievement of sustained concentrations in detriment 
of the localized therapy. 
On the other hand, pharmacological chaperone (PC) therapy is an emerging 
therapeutic approach for the treatment of protein misfolding diseases, which consists of 
a diverse group of disorders associated with the incorrect folding of specific proteins.[1] 
Some misfolding diseases are due to missense protein mutations that cause abnormal 
conformations and the consequent loss of the function. PC therapy is based on the use 
of small molecule ligands (i.e. the PCs) that selectively bind and stabilize mutated 
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proteins, thus, favoring their correct conformation.[2] Therefore, the activity of the 
mutated proteins is partially rescued, which has a favorable impact on the patient status 
and the rate of disease progression.  
This work aims to design a long-term delivery polymer vehicle for polar hydrophilic 
drugs, which does not affect the bioactivity. For this purpose, we have chosen ambroxol 
hydrochloride (AH; Scheme 1), a mucolytic agent that potentiates the activity of sodium 
channels, which has been shown to act also as a PC for the lysosomal enzyme -
glucocerebrosidase (GCase). Mutations in the GCase gene cause Gaucher's disease, 
which is the most prevalent lysosomal storage disease. AH has been shown to promote 
and stabilize the proper folding of GCase in the endoplasmic reticulum.[3] The PC role 
played by AH in the enhancement of the activity of misfolded GCase has been 
demonstrated using in vitro[3,4] and in vivo models.[5] Furthermore, recent clinical trials 
in patients with Gaucher disease showed that AH led to substantial clinical 
improvement.[6] 
 
Scheme 1. Chemical structure of AH.  
 
Although AH can be administered orally or through intravenous injection, the tissue 
distribution is unfortunately rather heterogeneous (e.g. AH is much easily distributed in 
lung tissue than in brain tissue)[3] and, therefore, its encapsulation into carriers to 
regulate its release might be highly desirable from a therapeutic point of view. In 
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general, on demand local delivery of drug molecules provides a means for effective 
drug distribution and dosing, fulfilling requirements for a variety of therapeutic 
applications while reducing the adverse effects of systemic drug administration.[7,8] 
Indeed, recent advances have facilitated the use of various cues, such as UV- and 
visible-wavelength light, NIR radiation, magnetic field, ultrasound or electrical 
stimulation to trigger the release of different types of drugs from smart materials.[8-10] 
Besides, as the utilization of PCs is a therapeutic paradigm recently launched, the 
encapsulation and release of these small ligands using polymeric scaffolds have not 
been explored yet. Studies oriented towards this aim might be useful in a near future.  
In this work we have engineered poly(-caprolactone) (PCL) layered systems 
consisting of electrospun microfibers (MFs), which successfully encapsulate the PC, 
protected with a coating that regulates the release. This protection has been achieved by 
sandwiching the loaded MFs between two outer spin-coated nanomembranes (NMs) or 
by dip-coating the loaded MFs into a polymer solution. Electrospinning is a well-known 
electrostatic technique that uses a high voltage field to charge the surface of a polymer 
solution droplet at the end of a capillary tube and induce the ejection of a liquid jet 
towards a grounded target (collector).[11] Morphology of fibers obtained in the collector 
depends on the solution properties (e.g. viscosity, dielectric constant, volatility and 
concentration) and operational parameters (e.g. strength of the applied electric field, 
deposition distance and flow rate), which should be conveniently addressed.[12] In recent 
years, electrospinning experienced a fast developing to simultaneous treatment of 
multiple fluids for creating complex nanostructures, such as core-shell, tri-layer from 
the coaxial and tri-axial electrospinning processes.[13] Although these core-shell 
nanostructures can provide tunable drug sustained release profiles,[14] the after-treatment 
of nanofibers from a single-fluid blending process represents another way for achieving 
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an improved sustained release. We have focused on this second approach which, due to 
its macro-scale nature, has the advantage of being more easily scaled-up. 
On the other hand, PCL has attracted an increasing interest in recent decades due to 
its biodegradability, easy processability and suitability for tissue engineering 
applications.[15] The use of this aliphatic polyester for biomedical applications was 
approved by the USA Food and Drug Administration (FDA) in the seventies and PCL 
can be found in many common sutures and suture components. Although small 
hydrophobic drugs were successfully loaded and smartly released from PCL electrospun 
fibers,[10,16] the polarity of the studied PC has motivated the design of the PCL-based 
layered systems to obtain slow and sustained release of active AH in physiological 
media. Thus, the polar hydrogen bonding acceptor and donor groups identified in the 
chemical structure of AH (Scheme 1) are expected to favor a very fast release rate in 
hydrophilic physiological environments, making difficult its dosage when continued 
administration is required. In order to avoid such limitation, which is can be 
extrapolated to other polar and hydrophilic drugs, in this work we propose different 




2.1. Materials  
PCL (Aldrich, UK, Mn:80,000), AH (Sigma, Italy), chloroform (Scharlau, Spain; 
stabilized with amylene, 99.8% pure), acetone (Sigma, South Korea, 99.9% pure) 
formic acid (FA; Panreac, E.U., 98% pure), and 2,2,2-trifluoroethanol (TFE; Sigma, 




2.2. Electrospinning  
PCL is frequently electrospun from chloroform or chloroform:acetone solutions[15b,16] 
but AH is insoluble in such organic solvents. However, AH can be solubilized in 
chloroform:acetone if either TFE or FA is present. Accordingly, electrospun MFs were 
prepared by dissolving PCL in a 2:1 v/v chloroform:acetone mixture while AH was 
dissolved in either TFE or FA. Electrospun AH-loaded PCL MFs coming from TFE and 
FA solutions have been denoted PCL/AH(TFE) and PCL/AH(FA), respectively, while 
unloaded PCL MFs (controls) are labelled as PCL(TFE) and PCL(FA). Although PCL 
and AH concentrations, as well as the electrospinning operational conditions, were 
optimized to avoid the formation of undesirable beads and droplets in PCL/AH(TFE) 
and PCL/AH(FA) MFs, only the optimized parameters are described below.   
Specifically, PCL/AH(TFE) MFs were prepared by dissolving 1.3 g of PCL in 7.5 
mL of a 2:1 v/v chloroform:acetone mixture using an incubator (37 ºC and 120 rpm) for 
12 h, while 0.0375 g of AH were added to 2.88 mL of TFE and vortexed extensively 
until completely dissolved. Then both solutions were thoroughly mixed together by 
additional strong vortexing. On the other hand, electrospun PCL/AH(FA) MFs were 
obtained by dissolving 1.3 g of PCL in 9.85 mL of the same 2:1 v/v chloroform:acetone 
solution. In this case, the PC was prepared by adding 0.0375 g of AH to 50 L of 2:1 
v/v chloroform:acetone. Then, 0.1 mL of FA was immediately added and the mixture 
was intensively vortexed until the drug was completely dissolved. Again, both solutions 
were mixed together with vigorous and extensive shaking. PCL(TFE) and PCL(FA) 
controls were prepared using identical procedures and solvents but without including 
the AH. The concentration of drug in PCL/AH(TFE) and PCL/AH(FA) MFs was below 
the cytotoxic threshold.[3] 
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Electrospinning was carried out in a non-conductor chamber. Solutions were loaded 
in a 10 mL BD Discardit (Becton Dickson Co., Franklin Lakes, NJ, USA) plastic 
syringe for delivery through a blunt-tipped (i.e. without bevel) 18 G needle (inner 
diameter 0.84 mm). The flow rate and the needle tip-collector distance were 5 mL/h and 
15 cm, respectively, for PCL/AH(TFE) and PCL(TFE), whereas these parameters 
changed to 4 mL/h and 25 cm, respectively, for PCL/AH(FA) and PCL(FA). The 
voltage, which was applied through a high-voltage Gamma High Voltage Research 
(ES30-5W) power supply, was 20 kV in all cases. All electrospinning experiments were 
carried out at room temperature. 
 
2.3. Spin-coating and dip-coating  
Poly(-caprolactone) nanomembranes (PCL NMs) were spin-coated for the 
preparation of multilayered AH-loaded systems. Spin-coating was performed with a 
spin-coater (WS-400BZ-6NPP/A1/AR1 Laurell Technologies Corporation). In all cases, 
the first PCL NM was spin-coated using a Teflon® square plate as substrate (area: 22 
cm2), which was previously cleaned by sonication in three different solvents (5 min 
each): milli-Q water, acetone and ethanol. For the fabrication of the PCL NMs, 1 mL of 
a 60 mg/mL polymer solution in acetone was first spin-coated onto the Teflon® 
substrate at 750 rpm for 1 min (first layer). After placing a 11 cm2 piece of an AH-
loaded fibrous mat on top of this layer, a second PCL NM was created by spin-coating 
under the same conditions (top layer). Alternatively, coating was also performed by 
dipping the fibrous mat for 3 seconds in a 60 mg/mL PCL solution in acetone (dip-
coating). In all cases, multilayered systems with non-drug-containing fibrous mats were 




2.4. Characterization of electrospun MFs and NMs 
The morphology and texture of electrospun MFs was examined by scanning electron 
microscopy (SEM) using a Focus Ion Beam Zeiss Neon 40 instrument (Carl Zeiss, 
Germany). Fibrous mats, which were cut in 11 cm2 samples, were mounted on a 
double-sided adhesive carbon disc and sputter-coated with a thin layer of carbon to 
prevent sample charging problems. All samples were observed at an accelerating 
voltage of 5 kV. Diameters of electrospun MFs were measured with the SmartTiff 
software from Carl Zeiss SMT Ltd. 
Atomic force microscopy (AFM) studies were conducted to obtain topographic and 
phase images of the surface of MFs using TAP 150-G silicon tapping probes.  Images 
were obtained with an AFM Dimension microscope using the NanoScope IV controller 
under ambient conditions in tapping mode. The root mean square roughness (Rq), which 
is the average height deviation taken from the mean data plane, was determined using 
the statistical application of the NanoScope Analysis software (1.20, Veeco). 
FTIR spectra were recorded with a Fourier Transform FTIR 4100 Jasco spectrometer 
(Jasco Analytical Instruments, Easton, USA) in the 4000–600 cm–1 range. An attenuated 
total reflection (ATR) system with a heated Diamond ATR Top-Plate (model MKII 
Golden Gate™, Specac Ltd., Orpington, UK) was used.  
Raman spectra were obtained using a Renishaw inVia Qontor confocal Raman 
microscope. The Raman setup consisted of a laser (at 532 nm with a nominal 250 mW 
output power) directed through a microscope (specially adapted Leica DM2700 M 
microscope) to the sample, after which scattered light is collected and directed to a 
spectrometer with a 2400 lines·mm−1 grating. The exposure time was 10 s, the laser 
power was adjusted to 0.1% of its nominal output power depending on the sample, and 
each spectrum was collected with five accumulations. 
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UV-vis absorption spectra were recorded to confirm the presence of AH in 
electrospun MFs. For this purpose, fibrous mats were cut into 11 cm2 samples, 
weighted and dissolved in 200 L of chloroform. Then, 1 mL of milli-Q water was 
added and vortexed for 5 min to extract the PC. The two phases were separated by 
centrifuging at 12900 rpm for 3 min. Spectra of the aqueous phase were obtained using 
a UV-vis-NIR Shimadzu 3600 spectrophotometer equipped with a tungsten halogen 
visible source, a deuterium arc UV source, a photomultiplier tube UV-vis detector, and 
a InGaAs photodiode and cooled PbS photocell NIR detectors. Spectra were recorded in 
the absorbance mode at room temperature, the wavelength range and bandwidth being 
190-400 nm and 2 nm, respectively.  
X-Ray photoelectron spectroscopy (XPS) analyses were performed in a SPECS 
system equipped with a high-intensity twin-anode X-ray source XR50 of Mg/Al (1253 
eV / 1487 eV) operating at 150 W, placed perpendicular to the analyzer axis, and using 
a Phoibos 150 MCD-9 XP detector. The X-ray spot size was 650 m. The pass energy 
was set to 25 and 0.1 eV for the survey and the narrow scans, respectively. Charge 
compensation was achieved with a combination of electron and argon ion flood guns. 
The energy and emission current of the electrons were 4 eV and 0.35 mA, respectively. 
For the argon gun, the energy and the emission current were 0 eV and 0.1 mA, 
respectively. The spectra were recorded with a pass energy of 25 eV in 0.1 eV steps at a 
pressure below 610-9 mbar. These standard conditions of charge compensation resulted 
in a negative but perfectly uniform static charge. The C 1s peak was used as an internal 
reference with a binding energy of 284.8 eV. The surface composition was determined 
using the manufacturer’s sensitivity factors. 
Contact angle (CA) measurements were conducted using the sessile drop method. 0.5 
µL of milliQ water drops were deposited onto the surface of the electrospun mats, 
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which were cut into rectangular pieces and fixed on a holder, and recorded after 
stabilization with the equipment OCA 15EC (DataPhysics Instruments GmbH, 
Filderstadt). The SCA20 software was used to measure the CA, which is shown here as 
the average of at least 40 measures for each condition.  
 
2.5. AH-Release experiments 
AH-loaded and unloaded (controls) fibrous mats were cut into small squares (11 
cm2), which were weighed and placed into Eppendorf tubes. Phosphate buffered saline 
(PBS) solution of pH 7.4 was considered as the release medium. Assays, which were 
performed in triplicate, were carried out by immersing sample mats in 1 mL of the 
release medium and using a rotating agitator. The medium was removed at 
predetermined time intervals and replaced by fresh one. The removed medium was used 
to quantify the released AH by measuring its absorbance in a UV-vis-NIR Shimadzu 
3600 spectrophotometer as described above. Finally, the mats were dissolved in 
chloroform and the residual PC was extracted for quantification. The calibration curve 
(y= 6.838·x, R2= 0.999) was obtained by plotting the absorbance against AH 
concentration from triplicate samples (Figure S1). On the other hand, PCL controls 
evidenced that the polymer degradation products do not interfere with the AH 
concentration measurements in long term assays.  
 
2.6. Evaluation of the activity of released AH 
Cell lysates, containing the lysosomal enzyme GCase, were obtained from IMR90 
fibroblasts (human lung fibroblasts, ATCC-CCL-186). For this purpose, fibroblasts 
were grown to confluence in 100 mm dishes using DMEM high glucose medium 
(Invitrogen) supplemented with antibiotics (100 U/mL penicillin/streptomycin, Gibco) 
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and 10% fetal bovine serum (FBS, Gibco) at 37 ºC in a 5% CO2 humidified atmosphere. 
Cells from each plate were detached with 1 mL of trypsin (0.05% trypsin/EDTA, 
Invitrogen) for 10 min at 37 ºC and 4 mL of fresh medium were added to re-suspend the 
cells. The concentration of cells was determined by counting in a Neubauer camera 
using trypan blue as a vital stain. For the biological assays, cells from three plates were 
transferred to a 50 mL conical tube and centrifuged (10 min, 300g), washed with PBS 
and centrifuged again. Cells were then re-suspended with 1 mL of PBS, counted, 
aliquoted and transferred to an Eppendorf tube and centrifuged (5 min, 600g). The 
final cell pellet was frozen in liquid nitrogen and stored at –80 ºC until use. 
Cell lysates were obtained from the harvested IMR90 fibroblasts. Aliquots of 
10.7106 cell pellets (each coming from three 100-mm dishes) were homogenized with 
450 µL of lysis buffer (100 mM NaCl, 1 mM MgCl2, 0.2% Triton X-100 (v/v), 10 mM 
HEPES, pH 7.4) containing 1 µg/ml aprotinin, 1 µg/ml leupeptin and 0.1 mM PMSF as 
protease inhibitors. Cells were broken by 20 strokes using an Eppendorf pestle and left 
on ice for 15 min. Cell debris was removed by centrifugation (600g, 5 min, 4 C) and 
the supernatant was aliquoted, frozen in liquid nitrogen and stored at –80 ºC. 
To check the activity of the AH released from the electrospun MFs and multilayered 
devices, a modification of the thermal denaturation and enzyme activity assays 
described by Diettrich et al.[17] and Maegawa et al.[3] was used. Briefly, cell lysates (23 
µL) were incubated for 60 min at 50 C with one volume of PBS either with or without 
AH (fresh or released from PCL-based systems). Samples were then kept on ice for 5 
min and left to equilibrate at room temperature for 5 more minutes. The same procedure 
using samples not submitted to thermal denaturation (kept on ice) was also carried out 
as a control. All the samples were prepared by duplicate. 
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GCase activity of the samples was tested using the fluorogenic substrate 4-
methylumbelliferyl-β-D-glucopyranoside, MUbGlc (Sigma). To do this, one volume (46 
µL) of substrate solution (12 mM MUbGlc, 50 mM sodium taurocholate, 0.2% Triton 
X-100 v/v, 0.2% human serum albumin w/v, 40 mM CaCl2 in McIlvaine’s citrate-
phosphate buffer, pH 5.40) was added to each sample. After incubation for 1 h at 37 ºC, 
the reaction was stopped by adding 2.5 volumes of stop solution (0.25 M 
Glycine/NaOH buffer, pH 10.5). Samples were placed in a 96-well black plate (300 
µL/well) and the fluorescence from the 4-methylumbelliferone (MU) reporter group 
released after hydrolysis of the substrate was measured in a microplate 
spectrofluorometer (Synergy HTX multimode reader, BioTek) with the excitation 
wavelength set at 360 nm and the emission wavelength at 460 nm. The relative 
remaining activity of GCase after thermal denaturation was calculated by comparison 
with the activity measured for the corresponding control samples kept on ice (i.e. not 
submitted to thermal denaturation).  
 
3. Results and discussion 
3.1. Preparation and characterization of AH-loaded fibers 
Mixtures of PCL dissolved in chloroform:acetone and AH dissolved in TFE or FA 
were electrospun to obtain PCL/AH(TFE) or PCL/AH(FA) MFs, respectively. The wt 
% of AH used in the feeding solution, which was identical in both cases, was 
completely incorporated into the PCL matrix during the electrospinning process. Figure 
1 compares SEM micrographs and diameter distributions of PCL/AH(TFE) and 
PCL/AH(FA) MFs obtained after optimization of the electrospinning conditions with 
those of unloaded PCL(TFE) and PCL(FA) control samples.  
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The utilization of TFE and FA resulted in the formation of well-defined MFs, in 
which droplets and beads were not detected. However, the morphology was seriously 
affected by both the incorporation of the drug into the polyester matrix and the effect of 
the solvent used to dissolve the PC in the viscosity of the feeding solution. More 
specifically, PCL/AH(FA) MFs present a cylindrical morphology with an average 
diameter (D) of 717±32 nm, while PCL/AH(TFE) MFs are much flatter, exhibiting a 
ribbon-like morphology and similar diameter (D= 694±13 nm). Both unloaded 
PCL(TFE) and PCL(FA) fibers exhibited cylindrical morphology, evidencing that, in 
spite of its low concentration, the influence of the PC in the viscosity of the feeding 
solution is much higher when it is dissolved in TFE than in FA. Clearly, this is due to 
the amount of TFE in the feeding solutions used to prepare PCL/AH(TFE) and 
PCL(TFE), which is almost 30 times greater than the amount FA in the solutions 
employed to electrospun PCL/AH(FA) and PCL(FA). The remarkable influence of the 
TFE solvent on the viscosity of the feed solution is confirmed by the diameter of 
PCL(TFE) MFs (D= 1488±88 nm), which is more than twice that of PCL(FA) MFs (D= 
633±33 nm).  
Interestingly, PCL/AH(TFE) and PCL/AH(FA) show well-adhered particles 
homogeneously distributed along surface of the MFs (Figure 1). These round-like 
particles, which exhibit a diameter of several hundred of nanometers and 100 nm for 
PCL/AH(TFE) and PCL/AH(FA), respectively, have been assigned to crystallized AH. 
These results have been attributed to the influence of AH···solvent interactions during 
the electrospinning process. Thus, the drug, which bears polar groups, forms crystalline 
domains that remain at the surface of hydrophobic PCL MFs when the electrospinning 
process causes the elimination of favorable AH···solvent interactions.[18] Moreover, the 
flat ribbon-like geometry of PCL/AH(TFE) fibers is probably due to the influence of 
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unfavorable PCL···AH interactions in the chain entanglement of the solution 
mixture.[18] Thus, both the incorporation of a low molecular weight drug and the 
formation of such PCL···AH interactions decrease the degree of chain entanglement in 
the feeding solution, which is a parameter that significantly influence the fiber 
morphology. 
AFM height and phase-contrast images are displayed in Figure 2 for all electrospun 
MFs, 3D topographic images being additionally included for PCL/AH(TFE) and 
PCL/AH(FA). AFM images are fully consistent with previously discussed SEM 
observations. Both AH-loaded and unloaded MFs present a very smooth surface, the 
roughness ranging from Rq= 62 nm for PCL/AH(TFE) to 163 nm for PCL(FA). 
Furthermore, AFM phase-contrast images obtained for PCL/AH(TFE) and 
PCL/AH(FA) allow to distinguish two materials with different elastic properties, which 
have been associated to the AH aggregates and the PCL matrix. This observation, which 
is much clearer for PCL/AH(TFE) than for PCL/AH(FA) due to the different sizes of 
AH aggregates, supports that the polar drug organizes in microphases separated from 
the non-polar polyester matrix.  
In order to corroborate that AH was successfully loaded in the PCL MFs, FTIR, 
Raman and UV-vis spectroscopic studies were conducted. Unfortunately, the FTIR 
spectra recorded for AH-loaded MFs were practically identical to the spectrum of 
unprocessed PCL powder and, therefore, the characteristic bands associated to the drug 
were undistinguishable (Figure S2). On the other hand, Figures 3a and 3b display the 
Raman spectra of electrospun MFs obtained using TFE and FA solvents, respectively. 
The spectrum of AH is included in both graphics for comparison. In addition to the 
bands observed for unloaded PCL, the spectra of AH-loaded MFs present some bands 
that have been associated to the PC. The weak bands at 1590 and 1555 cm-1, which are 
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detected in the spectra of both PCL/AH(TFE) and PCL/AH(FA), have been attributed to 
the primary and secondary amines of AH (Scheme 1), respectively.[19] Besides, the 
weak signals observed at around 800 cm-1 in the PCL/AH(TFE) spectrum have been 
related with the Ar-Br Raman active modes,[19] even though these are practically 
undetectable for PCL/AH(FA).  
The presence of AH in loaded MFs was also investigated by UV-vis spectroscopy. 
For this purpose 11 cm2 samples were cut from AH-loaded fibrous mats and dissolved 
in chloroform. Then, the PC was extracted using water, as described in the Methods 
section. UV-vis spectra of four different AH-containing aqueous solutions derived from 
PCL/AH(TFE) fibrous mats are displayed in Figure 3c together with the quantification 
of the PC. All spectra showed an absorption band at 307 nm, even though its intensity 
differs from sample to sample. Although the presence of the band confirms the 
successful loading of AH, the dispersion in the quantified value, with an average value 
of 1.540.64 w/w%, reflects that the drug is heterogeneously distributed in the PCL 
matrix. Similar results were observed in the spectra recorded from PCL/AH(FA) mats 
(Figure S3), the average content being in this case 1.550.81 w/w%. AH loading is 
further supported by the XPS atomic compositions obtained for the different studied 
MFs, which are compared in Table 1. Both N and Br are detected in PCL/AH(TFE) and 
PCL/AH(FA), while these atoms are absent in PCL(TFE) and PCL(FA).  
The water contact angle () of fibrous mats was determined for AH-loaded and 
unloaded PCL matrixes (Figure 3d). The contact angles indicate that all materials are 
hydrophobic (i.e.  > 90º) and, interestingly, the wettability does not change upon the 
incorporation of the polar PC. This behavior can be explained by the combination of 
three factors: i) the PCL matrix is hydrophobic; ii) the concentration of AH in the 
loaded fibers is very small; and iii) the micro-nanopatterned structure on the surface of 
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the mat. Regarding to the latter, the micrometric diameter of the electrospun fibers (i.e. 
0.6-1.5 m in Figure 1) combined with the nanometric roughness (i.e. 8-16 nm in 
Figure 2) and holes among neighboring fibers favor the entrapment of air, which may 
give place to a Cassie Baxter stable state.[20] 
 
3.2. Release from loaded fibers 
AH release from loaded electrospun MFs is expected to depend on the relative 
strength of the interactions between the drug and the PCL matrix or the molecules from 
the release medium (i.e. water and ions). AH-loaded and unloaded (negative control) 
fibrous mats were immersed in PBS using Eppendorf tubes, as described in the Methods 
section. At regular time intervals (i.e. 5, 15, 30, 45, 60, 90, 120, 360, 1440 min), release 
medium (1 mL) was withdrawn from the tube, replaced by 1 mL of fresh medium, and 
analyzed by UV-vis spectroscopy. The amount of AH released to the medium was 
quantified using the band centered at 307 nm, which corresponds to the PC.  
Figure 4a compares the UV-vis spectra of the released media extracted after 5, 15, 30 
and 60 min from samples consisting of PCL/AH(TFE) mats immersed in PBS. The 
content of AH in the release medium was high at the beginning and decreased very 
rapidly with time (i.e. from 1.59 w/w % after 5 min to 0.06 w/w % after 60 min), 
evidencing a very fast release. Accordingly, the release curve (Figure 4b) indicates that 
80% of the PC was released to the PBS medium during the first 15 min, whereas the 
amount of AH that remained in the MFs after 6 h was lower than < 1%. The behavior of 
samples from PCL/AH(FA) mats immersed in PBS was practically identical, as 
reflected in the UV-vis spectra and the release curve displayed in Figures S4a-b. The 
very fast release in PBS has been associated to the weakness of AH···PCL interactions, 
which are expected to be rapidly compensated by the strong interactions between the 
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polar groups of AH and the components of PBS medium. In order to enhance the 
efficiency of therapies based on the controlled release of polar drugs, the fast 
mechanism observed for loaded PCL MFs requires modification into an extended 
release mechanism. For this purpose, in the following sub-sections we first demonstrate 
the activity of the released AH and, then, we show how different coating strategies 
allow to delay and regulate the drug release dosage. 
 
3.3. Activity of released AH 
Many lysosomal storage disorders (LSDs) originate from mutations that affect the 
proper folding of the enzyme in the ER. PCs allow mutant enzymes to be correctly 
folded, thus avoiding endoplasmic reticulum retention and granting their transportation 
to the lysosomes, where the enzyme–PC complex dissociates due to the low pH and 
high substrate concentration.[21] Specifically, AH has been reported to be an excellent 
PC candidate for Gaucher disease, which is the most common autosomal recessive 
LSD.[3,22] Gaucher disease is caused by mutations in the gene encoding lysosomal 
GCase and ultimately resulting in the accumulation of glucosylceramide in 
macrophages and the development of hepatosplenomegaly, anaemia, skeletal lesions 
and central nervous system dysfunctions.[23]  
Previous studies pointed to the efficacy of AH in increasing GCase activity[3,6] and 
thermal stability.[3,22] In this section, we examine if AH maintains this stabilizing 
activity once released from loaded electrospun PCL MFs. For this purpose, a thermal 
denaturation assay utilizing GCase from lysed fibroblasts was conducted in the absence 
or in the presence of both fresh and released AH (see Methods section). Residual GCase 
activity after thermal denaturation was standardized by comparison with the GCase 
activity obtained from the sample that was kept at 0 ºC (non-denaturation control). 
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Enzyme activity was evaluated by measuring the fluorescence resulting from the release 
of the fluorescent reporter 4-MU group from the substrate. Thus, the remaining activity 
in the presence of either fresh or released AH was obtained dividing the fluorescence 
measured for the thermally denatured samples by the fluorescence of the corresponding 
sample kept at 0 ºC.  
Figure 4c compares the remaining activity of GCase after thermal denaturation in the 
presence of the AH released from PCL/AH(TFE) and PCL/AH(FA) MFs after 5 min in 
PBS, fresh AH in PBS, and PBS alone (without AH). Results show the protecting effect 
on GCase activity of AH, which is in agreement with the reported literature.[3] Thus, all 
the samples of GCase that have been submitted to heating in the presence of AH (either 
fresh or released from the fibers) show more activity than the enzyme sample heated 
without AH being present. Moreover, the GCase activity is slightly higher in the 
presence of AH released from MFs than with fresh AH, showing that the functionality 
of the PC is not damaged by the aggressive conditions of the electrospinning process. 
These results indicate that PCL is a suitable vehicle to encapsulate biactive polar drugs 
such as AH and, thus, improvement of the release mechanism to obtain a gradual 
dosage deserves consideration. 
 
3.4. Regulating the AH release by applying coating strategies 
In order to delay the delivery of the PC, two different coating approaches were 
examined. In the first one, PCL/AH(TFE) and PCL/AH(FA) fibrous mats were 
sandwiched between two spin-coated PCL NMs. The process used to prepare these 3-
layered NM/MFs/NM systems, hereafter denoted PCL//PCL/AH(TFE)//PCL and 
PCL//PCL/AH(FA)//PCL, respectively, is summarized in Figure 5a. Free-standing 
sandwiched systems were prepared by spin-coating a PCL NM onto a Teflon® substrate 
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using an acetone polymer solution (see Methods). Then, a 1 cm2 PCL/AH(TFE) or 
PCL/AH(FA) square piece, which was cut from the corresponding fibrous mat, was put 
onto the first PCL NM and the second PCL NM was spin-coated onto it. Finally, the 
sandwiched system was easily detached from the Teflon® substrate. It is worth noting 
that the solubility of PCL in acetone is very slow, especially with respect to chloroform 
or chloroform:acetone mixtures, which allowed to minimize the attack of the solvent to 
the PCL MFs during the spin-coating process. Sandwiched systems using unloaded 
PCL(TFE) and PCL(FA) fibrous mats were also prepared as controls for release assays. 
Sandwiched systems supported onto the Teflon® substrate were employed for SEM 
characterization. 
In the second coating strategy, AH-loaded fibrous mats were modified through a dip-
coating method, as schematically described in Figure 5b. More specifically, 11 cm2 
PCL/AH(TFE) and PCL/AH(FA) square pieces were immersed in a solution of PCL in 
acetone for 3 s. The resulting samples, hereafter denoted PCL[PCL/AH(TFE)] and 
PCL[PCL/AH(FA)], were dried and used for release assays. Control samples were 
prepared using unloaded fibrous mats.  
SEM micrographs of the bottom PCL NM and the two sandwiched systems are 
displayed in Figure 6a. The bottom PCL NM presents a very flat, homogeneous and 
smooth surface, the thickness being of only 74785 nm. In contrast, the shape of the top 
PCL layer adapts to the ribbon-like and the cylindrical morphology of PCL/AH(TFE) 
and PCL/AH(FA) MFs, respectively, acting as a coating. It is worth noting that, in the 
latter case, the top PCL NM wraps perfectly the MFs and the only fingerprint of its 
presence corresponds to the pseudo-periodic folds that systematically appears in the 
direction perpendicular to the fiber axis. These folds can be associated to the effect of 
the acetone used to dissolve PCL. In contrast, the PCL NM spin-coated onto 
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PCL/AH(TFE) MFs exhibits a heterogeneous aspect. In these samples, regions 
involving wrapped MFs with the previously described folds coexist with small areas in 
which the structure of the MFs is no longer distinguishable, which is probably due to 
the flat morphology of the ribbon-like PCL/AH(TFE) MFs.  
SEM micrographs of PCL[PCL/AH(TFE)] and PCL[PCL/AH(FA)] are displayed in 
Figure 6b. Although the morphologies of the latter systems are apparently similar to 
those obtained for PCL//PCL/AH(TFE)//PCL and PCL//PCL/AH(FA)//PCL, detailed 
inspection evidences important differences. For example, PCL[PCL/AH(FA)] shows a 
heterogeneous structure in which neighboring MFs are partially joined by irregular 
portions of films formed after solvent evaporation, while these elements are 
imperceptible in PCL[PCL/AH(TFE)]. In contrast, the density of folds is much lower at 
the surface of PCL[PCL/AH(TFE)] than at the surface of all the other coated systems. 
Overall, these differences indicate that the dip-coating technique is much more 
influenced by the morphology of the MFs than the spin-coating.  
The water contact angle of fibrous mats coated with PCL by spin-coating and dip-
coating are displayed in Figures S5 and S6, respectively. The measured contact angles 
ranged from 85º to 99º, evidencing a significant reduction with respect to uncoated 
fibrous mats (Figure 3d). This reduction has been attributed to the fact that the external 
coating eliminates the micro-nanopatterned structure found on the surface of the fibrous 
mats. Thus, the PCL coating dominates the wettability of the new scaffolds, which 
exhibit in all cases contact angles close to the lowest threshold of hydrophocity (i.e.  > 
90º).  
Figure 7 compares the release profiles of AH-loaded systems prepared by spin-
coating and dip-coating. The release was very slow in all cases, even though with some 
differences. For example, a release percentage of 95% was reached after 2 and 1 
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months of exposure to the medium for sandwiched and dip-coated systems, 
respectively, while the time required by uncoated MFs was only 1 h. Accordingly, the 
coating has a very significant impact in the kinetics of the release. Moreover, the extent 
of the delay in the release of the PC largely depends on the technique used to protect the 
MFs. The delay is much longer when fibrous mats are sandwiched between two spin-
coated NMs than when coated through simple immersion in a PCL solution. Indeed, the 
effect of the coating technique is observed even in the first steps of the release, as 
evidenced in the insets displayed in Figure 7. Thus, the release profiles obtained for 
PCL//PCL/AH(TFE)//PCL and PCL//PCL/AH(FA)//PCL are very similar for both short 
and large times of exposure, which indicate that the protection imparted by 
homogeneous spin-coated NMs does not depend on the morphology of the fibrous mats. 
In contrast, the profiles obtained for PCL[PCL/AH(TFE)] and PCL[PCL/AH(FA)] 
present important differences, especially for short times (e.g. after 6 h of exposure the 
release percentage was 64% and 42% for the former and the latter, respectively). These 
differences are attributed to the heterogeneous structure of the systems prepared by dip-
coating (Figure 6), which is apparently affected by the morphology of the MFs. 
Figure 8 compares the time required to release 50% and 80% of loaded AH from all 
the studied systems. A it was expected, the delivery of coated systems was clearly 
delayed with respect to that observed from the MFs alone since AH had to diffuse 
through the PCL coats. However, the most remarkable result displayed in Figure 8 is 
that it demonstrates that the AH release can be regulated through the morphology of the 
scaffold without changing the composition of the PCL matrix. Thus, the time required 
for release can extend from a few minutes for uncoated MFs to few days or almost a 





The present study reveals that AH, a small and polar PC that increases the activity of 
misfolded GCase, can be loaded in fibrous PCL scaffolds by electrospinning. The fast 
release rate of this drug from such fibrous scaffolds, which occurs in less than an hour, 
has been controlled by applying external coatings to the MFs. These coatings, which 
have been achieved by dip-coating and by spin-coating, have been obtained using PCL 
dissolved in acetone to avoid the rapid dissolution of the AH-loaded MFs. The AH 
release extends to weeks and months when coated fibrous scaffolds are prepared by dip-
coating and spin-coating, respectively. The released AH retains the protecting effect on 
the activity of GCase, demonstrating that the electrospinning process does not affect the 
functionality of the drug. Moreover, PCL coated-fibrous scaffolds can be used to 
regulate strategically the dosage of polar drugs depending on the therapeutic needs. 
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Table 1. Atomic percent composition obtained by XPS for AH-loaded and unloaded 
PCL fibers.  
 
 C N O Br 
PCL/AH(TFE) 81.81 0.19 17.95 0.05 
PCL(TFE) 80.04 - 19.96 - 
PCL/AH(FA) 81.77 0.12 18.08 0.03 





CAPTIONS TO FIGURES 
Figure 1. SEM micrographs taken at low (left) and high (center) magnification for 
electrospun fibers of PCL/AH(TFE), PCL(TFE), PCL/AH(FA) and PCL(FA). The 
diameter distribution of the electrospun microfibers and the corresponding average 
value  standard deviation are displayed at the right. Particles adhered to the surface of 
the PCL matrix, which have been associated to the crystallized drug, are marked by red 
boxes for PCL/AH(TFE) and PCL/AH(FA).  
Figure 2. AFM images of PCL/AH(TFE), PCL(TFE), PCL/AH(FA) and PCL(FA): 
2D height (left), 3D topographic (center; only for AH-loaded MFs) and phase-contrast 
(right) images. The root mean square roughness (Rq) is displayed for each system. 
Figure 3. Comparison between the Raman spectra recorded for: (a) PCL/AH(TFE), 
PCL(TFE) and AH; and (b) PCL/AH(FA), PCL(FA) and AH. The weak peaks 
associated to AH in the spectra of PCL/AH(TFE) and PCL/AH(FA) are marked by the 
colored bars. (c) UV-vis spectra of the AH-containing water solutions extracted from 
four samples of PCL/AH(TFE) MFs dissolved in chloroform (left) and quantification of 
the AH contained in the extraction medium (right). The spectra corresponding to the 
PCL/AH(FA) mats are displayed in Figure S3. (d) Contact angle for water of 
PCL/AH(TFE), PCL(TFE), PCL/AH(FA) and PCL(FA) fibrous mats. 
Figure 4. (a) UV-vis spectra of the PBS release media withdrawn at selected time 
intervals from Eppendorf tubes containing samples of PCL/AH(TFE). (b) AH release 
profile in PBS from PCL/AH(TFE) MFs. Complete description of the procedure 
employed for the release assays is provided in the Methods section. Results obtained for 
PCL/AH(FA) MFs are displayed in Figure S4. (c) Remaining GCase activity (%) (i.e. 
ratio between the enzymatic activity after thermal denaturation compared with the 
activity of the enzyme kept at 0 ºC) in the presence of AH released from PCL/AH(TFE) 
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and PCL/AH(FA) fibrous mats after 5 min immersed in PBS, fresh AH in PBS and 
without AH (PBS alone).  
Figure 5. Procedure used to prepare: (a) free-standing PCL//PCL/AH(TFE)//PCL 
and PCL//PCL/AH(FA)//PCL by sandwiching the fibrous mat between two spin-coated 
PCL NMs; (b) Preparation of PCL[PCL/AH(TFE)] and PCL[PCL/AH(FA)] by dip-
coating fibrous mats.  
Figure 6. SEM micrographs of: (a) the PCL NM and the PCL//PCL/AH(TFE)//PCL 
and PCL//PCL/AH(FA)//PCL sandwiched systems obtained by spin-coating (Figure 
5a). Representative regions in which the morphology of PCL/AH(TFE) MFs is lost are 
indicated by blue ellipsoids; (b) PCL[PCL/AH(TFE)] and PCL[PCL/AH(FA)] obtained 
by dip-coating (Figure 5b). Irregular portions of films joining neighboring MFs are 
indicated by yellow squares.  
Figure 7. AH release profile in PBS from (a) sandwiched and (b) dip-coated 
systems.  
Figure 8. Comparison of the time required to release 50% and 80% of the loaded AH 













































































































TOC text: The release of bioactive ambroxol, a pharmacological chaperone for 
Gaucher disease, from polyester scaffolds has been regulated (from a few hours to 
months) by controlling their geometry. For this purpose, the utilization of electrospun 
fibers (release rate: few hours) has been combined with dip-coating and spin coating 
techniques (release rate: weeks and months, respectively). 
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